Translator Disclaimer
1 June 2004 Intrapituitary Regulatory System of Proliferation of Mammotrophs in the Pituitary Gland
Author Affiliations +
Abstract

Anterior pituitary cells produce growth factors plus cytokines and their receptors. Although some of these pituitary growth factors and cytokines are known to be involved in the control of cell differentiation, proliferation and hormone production in the pituitary gland, their physiological roles remain unknown. Lots of evidence indicates that they are involved in the regulation of prolactin-secreting mammotroph cell proliferation. The regulation of mammotroph functions is a suitable system for understanding the intrapituitary regulatory system operated by growth factors and cytokines, since mammotrophs are the most actively proliferating cells in female pituitary glands. This review discusses the possible intrapituitary regulation of mammotroph differentiation and proliferation in rat and mouse pituitaries.

INTRODUCTION

Pituitary glands in mammals consist of neurohypophysis and adenohypophysis, the latter of which can be further divided into anterior and intermediate lobes. These glands constitute a functional link between the nervous system and endocrine system, regulating various functions including growth, energy metabolism, osmoregulation, reproduction and behavior. Organogenesis and initial cytodifferentiation of pituitary glands are regulated by factors produced by two opposing signaling gradients. One signal is generated by the ventral floor cells of the diencephalons, while the other is generated by oral ectodermal cells (Dasen et al., 1999; Scully and Rosenfeld, 2002). After the initial differentiation of different cell types, the cell populations of each secretory cell type expand by proliferation. Thus, pituitary cells appear to proliferate by self-duplication, however, other types of growth cannot be ruled out.

The proportions of each hormone secretory cell type vary with age or alterations in physiological status. Secre-tory cell numbers are determined by the balance between the proliferation and apoptosis of pituitary secretory cells, which is partly regulated by growth factors and cytokines produced in the pituitary gland as well as hypothalamic hormones and hormones from the target organs (Schwartz and Cherny, 1992; Denef, 1994; Takahashi, 1995; Renner et al., 1996; Ray and Melmed, 1997; Schwartz, 2000). This review describes the actions of growth factors produced within the pituitary gland and shows the intrapituitary regulatory system involved in controlling pituitary functions. Of the several types of pituitary cells, the proportion of mammotrophs differs between males and females (Takahashi and Kawashima, 1982), and changes during pregnancy and lactation (Haggi et al., 1986). In addition, the regulation of mammotroph proliferation has been well studied compared to other types of anterior pituitary cells; therefore this study focuses on the proliferation and differentiation of mammotrophs.

DEVELOPMENT OF PITUITARY GLANDS AND MAMMOTROPH DIFFERENTIATION

Pituitary gland development is regulated by extrinsic and intrinsic signals that control the expression of several transcription factors. Two highly related paired-like home-odomain factors, Hesx1/Rpx and an activator prophet of Pit-1 (Prop-1), are thought to play essential roles in the morpho-genesis of pituitary glands (review, Olson et al., 2003). Hesx1/Rpx appears to be important for the initial progression of pituitary development, while its subsequent down-regulation leads to the emergence of Prop-1-dependent lineages (Gage et al., 1996; Sornson et al., 1996). Prop-1 is required for the initial proliferation of Pit-1-dependent thyrotrophs, somatotrophs, mammotrophs and gonadotrophs (Gage et al., 1996; Sornson et al., 1996). Pit-1, the POU domain protein, is expressed in thyrotrophs, somatotrophs and mammotrophs, and is required for the differentiation of these cell lineages (Li et al., 1990). The Pit-1-related cell lineage is a clearly understood model system of cell differentiation. The differentiation of thyrotrophs, somatotrophs and mammotrophs is mediated via the reciprocal interactions of two transcription factors, Pit-1 and GATA2 (Dasen et al., 1999). In thyrotrophs, both Pit-1 and GATA-2 are expressed, and Pit-1 is required for the activation of growth hormone (GH) and prolactin (PRL) genes.

Several reports suggest that mammotrophs are trans-differentiated from somatotrophs under estrogen stimulation and/or other factors (Boockfor et al., 1986; Behringer et al., 1988; Borrelli et al., 1989; Inoue and Sakai, 1991; Kineman et al., 1992; Kakeya et al., 2000), and that the transdifferentiation of pre-existing somatotrophs into mammotrophs is a post-mitotic event (Goda et al., 1998; Kakeya et al., 2002). This transdifferentiation seems to contradict the self-duplication of mammotrophs described above. However, several reports suggest that transdifferentiation into mammotrophs without mitosis occurs during the prenatal and early postnatal period as well as during late pregnancy and lactation in rats allowing generation of a large number of mammotrophs in a short period of time (Frawley and Boockfor, 1991; Takahashi, 1992).

MAMMOTROPH PROLIFERATION

Mammotrophs are the most actively proliferating cells in rat and mouse pituitaries (Shirasawa and Yoshimura, 1982; Takahashi and Kawashima, 1982; Takahashi, 1992; Takahashi, 1995). In adult female rats the mitotic activity of mammotrophs is higher during estrus than during any other stage of the estrous cycle (Takahashi et al., 1984; Oishi et al., 1993). This high proliferation of mammotrophs depends upon ovaries or ovarian estrogen, since ovariectomy decreased the high mitotic activity observed during estrus, while estrogen replacement increased mitotic activity. This sexual difference in mitotic activity is thought to lead to the sexual difference in mammotroph number (Takahashi and Kawashima, 1982; Sasaki and Iwama, 1988).

A sex-difference in mammotroph development has been observed in rats and mice. In mouse pituitaries, for example, the total number of mammotrophs did not differ between sexes at 14 and 21 days of age, but at 35 days of age female pituitaries contained more mammotrophs than male pituitaries by approximately three-fold. At 60 days of age the number of mammotrophs in the female mice was twice that of the male mice (Takahashi, 1995). This difference in the growth pattern of mammotroph populations is thought to be due to a difference in the proliferation of mammotrophs between male and female mice. Maternal estrogens may be involved in the growth of mammotrophs during the perinatal period. The factors that enhance mammotroph proliferation during the neonatal period remain to be clarified, although the involvement of a milk-borne factor of maternal origin in mammotroph differentiation had been already reported (Porter et al., 1993).

Pituitary gland growth is stimulated by estrogen, and an increased number of mammotrophs can be observed in estrogen-treated rats and mice. The proliferation of mammotrophs is regulated by estrogen (Lloyd et al., 1975; Takahashi et al., 1984; Takahashi and Kawashima, 1987; Oomizu and Takahashi, 1996). This estrogenic effect might be mediated directly through changes in the expression of genes essential to the cell cycle. Estrogen stimulates the expression of cell-cycle-regulatory proteins such as cyclins and cyclin-dependent kinase inhibitors, which lead to the progression of the cell cycle (review: Pestell et al., 1999; Foster et al., 2001). On the other hand, several studies on estrogen-responsive tissues have suggested that the effect of estrogen on cell proliferation is mediated by growth factors whose production is stimulated by estrogen in an autocrine or paracrine manner (Sirbasku, 1978; Sutherland et al., 1988). The following sections discuss some of the growth factors involved in mammotroph growth.

Transforming growth factor-α (TGF-α)

TGF-α, an epidermal growth factor (EGF), binds to EGF receptors (Massague, 1990) and stimulates DNA-replication of mammotrophs in serum-free primary cultures of mouse anterior pituitary cells (Oomizu et al., 2000). TGF-α gene expression is stimulated by estrogen in ovariectomized mice (Sharma et al., 2003). Borgundvaag et al. (1992) showed a concurrent increase in TGF-α mRNA and pituitary weights in chronic estrogen-treated rats. Treatment of mouse pituitary cells with a combination of estradiol (E2) and anti-TGF-α antibodies did not increase the number of DNA-replicating cells (Sharma et al., 2003). Thus, immunoneutralization with anti-TGF-α antibodies blocked the estrogen-induced proliferation of mammotrophs. Moreover, the blockade of TGF-α message translation was attempted by TGF-α-antisense oligodeoxynucleotide treatment resulting in the inhibition of estrogen-induced mammotroph proliferation (Oomizu et al., 2000). These findings suggest that TGF-α acts as an estrogen-induced growth factor in the anterior pituitary glands, stimulating DNA replication and mammotroph mitosis.

The overexpression of human TGF-α in transgenic mice accelerated the development of pituitary mammotrophic adenomas (McAndrew et al., 1995). Furthermore, in pituitary tumor cells, TGF-α affected cell proliferation in either a stimulatory or inhibitory manner (Ramsdell, 1991; Finley et al., 1994). TGF-α is therefore also involved in the growth of pituitary tumor cells.

TGF-α is produced in the pituitary glands of several species (Kudlow and Kobrin, 1984; Kobrin et al., 1987; Lazar and Blum, 1992). In rat pituitary cells, TGF-α mRNA expression was detected in somatotrophs, gonadotrophs and mammotrophs (Fan and Childs, 1995) while in mouse pituitaries TGF-α mRNA-expressing cells are evenly distributed throughout the anterior pituitary gland, but not in the intermediate or posterior lobes (Sharma et al., 2003). TGF-α mRNA-expressing cells are medium-sized and either round or oval. In adult male and female mouse pituitaries, TGF-α mRNA-expressing cells account for 65 and 55% of all pituitary cells, respectively. To determine TGF-α mRNA-expressing cell types in mouse pituitaries, serial sections were studied by non-radioisotopic in situ hybridization using cDNA probes for TGF-α mRNA, GH mRNA and PRL mRNA. Most of the GH mRNA-expressing cells contained TGF-α mRNA (79–83%), whereas only a small population of PRL mRNA-expressing cells contained TGF-α mRNA (1–3%) (Sharma et al., 2003). An immunocytochemical study also showed that somatotrophs express TGF-α mRNA (Takahashi et al., 2002). This discrepancy between TGF-α-mRNA expressing cell types might be partly based upon the different animal species studied. These findings indicate that the main source of TGF-α is somatotroph populations, since somatotrophs are the most abundant cells in anterior pituitary glands. In rat and mouse pituitaries, for example, somatotrophs and mammotrophs are distributed evenly throughout the anterior lobes of the pituitary glands. Based on the morphological analysis of TGF-α expression in mouse pituitaries, it is likely that TGF-α produced in the somatotrophs acts on mammotrophs in a paracrine manner.

Immunoreactive EGF receptors have been observed in all subsets of rat pituitary secretory cells, but are only present in a fraction of these cells (Fan and Childs, 1995; Honda et al., 2000). EGF receptor expression changes with various conditions such as stress and the estrous cycle (Fan and Childs, 1995; Armstrong and Childs, 1997a, b). Similarly, estrogen treatment with E2 increases EGF receptor mRNA in mouse pituitaries (Oomizu et al., 2000). Estrogen appears to stimulate pituitary growth at the level of EGF receptor production as well as TGF-α production. To study whether TGF-α mediates the estrogen-induced proliferation of mammotrophs, a specific inhibitor of EGF receptors, 3,4-dimethoxy-a-(3-pyridyl)-(Z)-cinnamonitrile (RG-13022) has been used (Yoneda et al., 1991). RG-13022 (10−7 M) was seen to significantly inhibit the EGF (10 ng/ml)-induced increase in DNA-replicating cells. E2-induced pituitary cell proliferation was also inhibited by RG-13022. Therefore, EGF receptor signaling is thought to be involved in the proliferation of pituitary cells, and to be required for pituitary cell differentiation during early pituitary organogenesis (Roh et al., 2001).

Epidermal growth factor (EGF)

EGF treatment increases PRL release (Aanestad et al., 1993), and stimulates the proliferation of mammotrophs and corticotrophs (Honda et al., 2000; Oomizu et al., 2000). EGF also stimulates the differentiation of mammotrophs in normal pituitary cells (Felix et al., 1995) and pituitary tumor cell lines (Inoue and Sakai, 1991; Kakeya et al., 2000). In rat pituitaries, somatotrophs and gonadotrophs express EGF mRNA, while cold stress induces EGF mRNA expression in corticotrophs and thyrotrophs (Fan and Childs, 1995). In mouse pituitaries, EGF mRNA expression was observed in somatotrophs and mammotrophs, but not detected in corticotrophs, thyrotrophs or gonadotrophs (Honda et al., 2000). Estrogen has been shown to stimulate EGF release from rat pituitary cells (Mouihate and Lestage, 1995). Therefore, EGF might also be involved in estrogen-induced mammotroph proliferation.

Transforming growth factor β (TGF-β)

TGF-β is a member of the cytokine family that regulates the differentiation and proliferation of various tissues. TGF-β1, -β2, and -β3 are synthesized in mammalian tissues. TGF-β1 inhibits PRL gene expression (Abraham et al., 1998) and the proliferation of mammotrophs (Sarkar et al., 1992). At low concentrations, it slightly stimulates the DNA replication of mammotrophs (Qian et al., 1996). TGF-β1 also acts in G1 arrest during the cell cycle as a paracrine inhibitor of mammotroph proliferation, while p15 and p27, which are Cdk (cyclin dependent kinase) inhibitors, are functional mediators of TGF-β-induced cell cycle arrest (Qian et al., 1996; Frost et al., 2001). In human pituitary tumor cell lines, TGF-β1 induces apoptosis (Oka et al., 1999). Mammotrophs synthesize TGF-β1, and TGF-β1 synthesis is inhibited by estrogen (Burns and Sarkar, 1993; Qian et al., 1996). Estrogen-induced pituitary growth might therefore be associated with the estrogen-induced inhibition of pituitary TGF-β1 production, resulting in the reduced TGF-β1-induced inhibition of mammotroph proliferation. The expression of TGF-β type II receptors in pituitary cells is also reduced by estrogen treatment (De et al., 1996) while TGF-α expression is inhibited by TGF-β1 (Mueller and Kudlow, 1991), leading to a reduced TGF-α growth stimulatory signal.

TGF-β2 is produced in rat pituitary glands, but is not localized in mammotrophs. It exerts no significant effect on the proliferation of mammotrophs (Hentges et al., 2000). TGF-β3, on the other hand, is produced in mammotrophs and stimulates mammotroph proliferation (Hentges et al., 2000). Its synthesis is stimulated by estrogen. The immunoneutralization of TGF-β3 with anti-TGF-β3 antibodies nullified the estrogen-induced proliferation of mammotrophs. This mitogenic action of TGF-β3 on mammotrophs is indirect and mediated by basic fibroblast growth factor (bFGF) secreted from folliculostellate (FS) cells (Hentges et al., 2000).

Basic fibroblast growth factor (bFGF)

bFGF belongs to the fibroblast growth factor (FGF) family, and is the most abundant growth factor in normal pituitary glands (Gospodarowicz and Ferrara, 1989; Amano et al., 1993). bFGF is produced in FS cells (Ferrara et al., 1987; Amano et al., 1993), gonadotrophs (Schechter and Weiner, 1991; Schechter et al., 1995), and somatotrophs (Marin and Boya, 1995), and is involved in the regulation of PRL synthesis and secretion (Larson et al., 1990; Mallo et al., 1995). A reverse hemolytic plaque assay also revealed that bFGF promotes the differentiation of mammotrophs in neonatal rat pituitary glands (Porter et al., 1994). bFGF stimulates mammotroph proliferation in the presence of estrogen, indicating that it is an estrogen-dependent mitogenic factor for pituitary cells. Estrogen treatment stimulates TGF-β3 production, and TGF-β3 increases the release of bFGF from FS cells. The immunoneutralization of bFGF in a FS cell-conditioned medium inhibited its growth stimulatory action on mammotrophs (Hentges et al., 2000). It can be concluded therefore that bFGF is located downstream of the estrogen-TGF-β3 signaling cascade as described above, acting as a mediator of TGF-β3-induced mammotroph proliferation.

Estradiol and TGF-β3 stimulated bFGF production and release in FS cells obtained from F344 rats, but not in FS cells obtained from Sprague-Dawley (SD) rats (Oomizu et al., 2004). It is thought that the higher responsiveness of pituitary cells derived from Fisher 344 rats to estrogen in terms of pituitary growth is related to the difference in FS cell populations between Fisher 344 and SD rats.

Insulin-like growth factor (IGF)

IGF-I and -II are produced in a number of tissues including the pituitary glands, and regulate the proliferation and differentiation of various cells in an autocrine and/or paracrine manner (Fagin et al., 1988; Bach and Bondy, 1992; Ren et al., 1994; Yokoyama et al., 1997; Gonzalez-Parra et al., 2001). In human pituitary glands, IGF-I-expressing cells are not hormone-secreting cells (Ren et al., 1994) while in rat pituitaries IGF-I mRNA-expressing cells were detected, but their cell types were not determined (Bach and Bondy, 1992). In situ hybridization and immunocytochemistry revealed that IGF-I is produced in the somatotrophs of mouse pituitaries (Honda et al., 1998). In normal human and rat pituitaries, IGF-II-expressing cells have not been determined (Haselbacher et al., 1985; Bach and Bondy, 1992).

Pituitary cells express type 1 IGF receptors (IGFR1) and type 2 IGF-I receptors (IGFR2) (Bach and Bondy, 1992; Ren et al., 1994; Gonzalez-Parra et al., 2001). In mouse pituitaries, IGFR1 is expressed in somatotrophs and some corticotrophs (Honda et al., 1998), while in rat pituitaries it is found in the gonadotrophs (Unger and Lange, 1997). IGFR2 is localized in somatotrophs as well as other types of cells in rat pituitaries (Ocrant et al., 1989). IGF-I was seen to stimulate the proliferation of anterior pituitary cells, in particular mammotrophs and corticotrophs, indicating that anterior pituitary cell proliferation is stimulated by IGF-I produced in the anterior pituitary cells (Oomizu et al., 1998). The mitogenic activity of IGF-I on mouse mammotrophs might be indirect, since mammotrophs in mouse pituitaries do not express IGFR1 (Honda et al., 1998). In rat pituitaries, IGF-I also stimulated vasoactive intestinal peptide (VIP) gene expression (Lara et al., 1994), which stimulates PRL release (Hagen et al., 1986; Nagy et al., 1988). Therefore, it is possible that VIP might mediate the effects of IGF-I on the mammotrophs. In addition, there are many reports showing that IGF-I regulates GH expression and secretion at the pituitary (Goodyer et al., 1984; Yamashita and Melmed, 1986) and/or hypothalamic level (Abe et al., 1983; Tannenbaum et al., 1983). IGF-I treatment was seen to decrease GH mRNA levels in mouse pituitaries (Honda et al., 2003).

Somatotrophs are the main source of pituitary IGF-I, while IGF-I gene expression was enhanced in GH-secreting tumor-bearing rats compared to control animals (Fagin et al., 1988). GH treatment also increased IGF-I mRNA levels in pituitary tumor GH3 cells (Fagin et al., 1989) and mouse pituitary cells (Honda et al., 2003). In addition, estrogen treatment for 54 days stimulated IGF-I expression in rat pituitaries (Michels et al., 1993), however, E2 treatments failed to stimulate IGF-I expression in mouse pituitaries. These discrepancies might be due to the different animal species studied, their sex, and/or the experimental protocols. The up-regulation of IGF-I transcription in the pituitary glands probably requires chronic E2 treatment. It is possible therefore, that GH and estrogen augment IGF-I production in somatotrophs, while enhanced IGF-I release stimulates the proliferation of mammotrophs through VIP production, since VIP receptors are expressed in mammotrophs (Wanke and Rorstad, 1990).

Nerve growth factor (NGF)

Nerve growth factor (NGF) is localized in rat mammotrophs and, together with PRL, its secretion is stimulated by VIP (Missale et al., 1996). The NGF receptor, gp140trk, is expressed in mammosomatotrophs and mammotrophs (Patterson and Childs, 1994a). NGF secretion is stimulated by interleukin-1β (IL-1β), and inhibited by GH releasing hormone, tumor necrosis factor-α (TNF-α) and bFGF (Patterson and Childs, 1994b). These results suggest that NGF is involved in the neuroendocrine-immune system. NGF promotes the differentiation and proliferation of mammotrophs, and NGF treatment was seen to stimulate the appearance of mammotrophs and increase the number of mammotrophs in rat pituitary cells (Missale et al., 1995). NGF treatment also stimulated the DNA replication of mammotrophs, corticotrophs and non-hormone containing cells (Proesmans et al., 1997). In pituitary tumor GH3 cells, NGF treatment decreased cell proliferation and GH secretion, but stimulated PRL secretion and dopamine receptor expression, suggesting that NGF induces the transdifferentiation of mammosomatotrophs into mammotrophs (Missale et al., 1994). NGF might therefore be involved in the functioning of mammotrophs in an autocrine manner.

Galanin

Galanin is synthesized in the central and peripheral nervous system as well as other tissues including anterior pituitary glands. Immunocytochemical studies of female rats at the light microscope level have shown that mammotrophs, somatotrophs, and thyrotrophs contain galanin, whereas male anterior pituitary gland mammotrophs do not (Kaplan et al., 1988; Hyde et al., 1991). Estrogen treatment is known to increase galanin mRNA production (Kaplan et al., 1988; Cai et al., 1998; Wynick et al., 1998), and galanin receptor (galanin-2 receptors) expression has been observed in rat anterior pituitary glands (Waters and Krause, 2000). Therefore, it is possible that galanin plays a paracrine role within the pituitary gland. The targeted over-expression of galanin in mouse pituitary cells increased the number of somatotrophs and mammotrophs, and serum PRL levels (Perumal and Vrontakis, 2003). These results suggest that galanin regulates PRL secretion and the proliferation of mammotrophs.

Vasoactive intestinal peptide (VIP)

VIP is synthesized in the jejunum and colon as a gastrointestinal hormone. It is also synthesized in the anterior pituitary gland, and is localized in subpopulations of mammotrophs (Morel et al., 1982; Koves et al., 1990; Chew et al., 1996) or other cell types (Lam et al., 1989; Carrillo and Phelps, 1992). VIP controls PRL secretion possibly in an autocrine manner (Nagy et al., 1988; Wanke and Rorstad, 1990; Escalada et al., 1996), and is probably involved in estrogen-induced changes in pituitary glands such as PRL secretion, the proliferation of mammotrophs and TGF-β1 synthesis, since estrogen stimulates VIP synthesis and release (Gomez and Balsa, 2003).

Calcitonin

Calcitonin is synthesized in the anterior pituitary gland, and localized in the gonadotrophs of rat pituitaries (Ren et al., 2001). Calcitonin receptors can also be detected in rat anterior pituitary glands (Sun et al., 2002). Calcitonin inhibits PRL secretion (Shah et al., 1988, 1996), and the proliferation of mammotrophs (Shah et al., 1999). This inhibitory action of calcitonin on mammotroph proliferation was attenuated by the immunoneutralization of TGF-β1 with anti-TGF-β1 serum. Calcitonin stimulates TGF-β1 synthesis, and increases the number of TGF-β1-expressing cells in female rat pituitaries. This finding indicates that the antiproliferative action of calcitonin on the mammotrophs is mediated by TGF-β1 (Wang et al., 2003), since TGF-β1, which is produced in mammotrophs, inhibits the proliferation of mammotrophs as described above. In rats, calcitonin synthesis is highest during the diestrus and lowest during the evening of proestrus, indicating that calcitonin gene expression is controlled by ovarian steroid hormones. Moreover, estrogen inhibits calcitonin expression, while progesterone does not, however, estrogen plus progesterone stimulates expression (Sun et al., 2002). Thus, estrogen inhibits TGF-β1 expression as well as calcitonin expression, and both are involved in the inhibition of mammotroph proliferation. On the other hand, estrogen stimulates the production of stimulatory factors for mammotroph proliferation such as TGF-α and bFGF, leading to an increased number of mammotrophs.

Tumor necrosis factor-α (TNF-α)

TNF-α is synthesized in somatotrophs and intermediate cells in rabbit pituitaries (Arras et al., 1996), and TNF-α receptors have been detected in mouse pituitary cells (Kobayashi et al., 1997). TNF-α induces apoptosis in somatotrophs and, in an estrogen-dependent manner, mammotrophs (Candolfi et al., 2002). It also decreases PRL release (Theas et al., 1998). TNF-α release from pituitary glands was higher during proestrus (Theas et al., 2000), thus TNF-α inhibits PRL secretion and mammotroph growth. This apoptotic effect of TNF-α plays a role in the turnover of mammotrophs during the estrous cycle in female rats and mice. As mentioned earlier, mammotrophs are the most actively proliferating cells in rat and mouse pituitaries (Takahashi, 1992). In adult female rats, the high mitotic activity of mammotrophs during estrus might lead to mammotroph growth (Takahashi et al., 1984). To maintain the number of pituitary cells, particularly mammotrophs, apoptotic regulation is necessary to reduce an increasing number of mammotroph cells during the estrous cycle and lactating period. Pituitary cell apoptosis might be regulated by TGF-β1 as well as TNF-α, since TGF-β1 induces apoptosis in human pituitary tumor cells (Kulig et al., 1999; Oka et al., 1999).

Proopiomelanocortin (POMC) peptides

POMC is synthesized and processed by proteolytic enzymes to produce three melanocyte-stimulating hormones (α, β-, and γ-MSH), adrenocorticotropic hormone (ACTH) and three endorphins (α-, β-, and γ-endorphins) in the anterior and intermediate lobes of pituitary glands. α-MSH is mainly produced in the intermediate lobes, while a light and electron microscopic study revealed that it is also produced in the corticotrophs of adult female rat pituitaries (Tanaka and Kurosumi, 1986). α-MSH stimulated PRL secretion and the proliferation of mammotrophs through melanocortin-3 receptor (MC3-R) (Morooka et al., 1998; Matsumura et al., 2003). Estrogen-induced acute PRL secretion is dependent on the neurointermediate lobe both in vivo (Murai and Ben-Jonathan, 1990) and in vitro (Ellerk-mann et al., 1991). It was revealed that the associated active substances are acetylated forms of α-MSH and β-endorphin (Ellerkmann et al., 1992a,b). Suckling-induced acute PRL release is also mediated by α-MSH probably secreted from the intermediate lobes (Hill et al., 1991). These results indicate that α-MSH augments the release of PRL, acting as a PRL-releasing factor. However, PRL-releasing factors other than POMC peptides might be involved in PRL secretion, since other PRL-releasing factors have been found in the intermediate lobes of rats (Laudon et al., 1990; Allen et al., 1995).

A radiolabeled α-MSH binding study of rat anterior pituitaries showed that α-MSH binding is restricted to a subset of pituitary cells (10.5%) and that all cells that bind α-MSH are mammotrophs (Zheng et al., 1997). On the other hand, in immature rat pituitaries, MC3-R mRNA-expressing cells are found in cells expressing GH mRNA alone or with PRL mRNA, TSHβ mRNA or POMC mRNA (Roudbaraki et al., 1999). These results suggest that MC3-R-expressing cells vary with postnatal development of the pituitary glands. The difference between these results regarding MC3-R mRNA-expressing cell types and the proportional abundance of each cell type might be due to differences in the ages of animals used. In mice, MC3-R mRNA is localized in most mammotrophs and some somatotrophs (Matsumura et al., 2003). Blood from the rat intermediate lobe to the anterior lobe flows through the portal link between the vascular network of the intermediate lobe and the sinusoidal capillaries of the anterior pituitary (Murakami et al., 1985). α-MSH released from the intermediate lobe can therefore reach mammotrophs in the anterior pituitary and stimulate PRL release and cell proliferation. In rat pituitaries, mammotrophs in the central region of the anterior pituitary stimulate PRL secretion and cell proliferation in response to α-MSH (Porter and Frawley, 1992). During the postnatal ontogeny period, α-MSH is clearly localized in the mouse anterior pituitary (Marcinkiewicz et al., 1993), while corticotroph subpopulations in adult female rat pituitaries produce α-MSH as described above (Tanaka and Kurosumi, 1986). Therefore, it is possible that α-MSH produced in the anterior pituitary controls the functioning of mammotrophs in a paracrine manner.

Tilemans et al. (1997) showed that γ3-MSH stimulated the proliferation of mammotrophs in aggregate immature rat pituitary cell cultures, and concluded that the mitogenic action of γ3-MSH is mediated by MC3-R. On the other hand, rat recombinant POMC (1-74) also stimulated the proliferation of mammotrophs, but was reportedly not mediated by MC3-Rs (Bert et al., 1999). New γ3-MSH receptors are known to be involved in the proliferation of mammotrophs (Langouche et al., 2002; Denef et al., 2003).

CONCLUSIONS

With aging and under various physiological conditions, pituitary secretory cells change in the number and proportion of each cell type. Regulation of pituitary cell proliferation and apoptosis is essential for the dynamic maintenance of pituitary cell populations. Of the pituitary cells, mammotrophs are the most actively proliferating in rats and mice (Takahashi, 1992). Estrogen controls the synthesis and release of growth factors and the expression of cell cycle associated genes, which in turn stimulate the proliferation of mammotrophs. Growth factors whose synthesis are up-regulated by estrogen directly promote DNA replication and the mitosis of mammotrophs, whereas growth factors whose synthesis are down-regulated by estrogen inhibit the mammotroph proliferation. In rat and mouse pituitaries, somatotrophs produce TGF-α, EGF, IGF-I and TNF-α, while mammotrophs produce TGF-β3, NGF, galanin and VIP. Calcitonin is synthesized in the gonadotrophs. Receptors for most of those growth factors can be detected in mammotrophs. These findings suggest that these growth factors regulate the function and proliferation of mammotrophs (Fig. 1). In addition, TGF-α, EGF, TGF-β3, bFGF, IGF-I, and galanin stimulate the DNA replication and proliferation of mammotrophs. The effect of TGF-β3 might be indirect, and mediated through bFGF. TGF-β3, TNF-α and calcitonin inhibit the DNA replication and proliferation of mammotrophs. TNF-α is also an apoptotic factor for mammotrophs. The anti-proliferative action of calcitonin on mammotrophs might be mediated by TGF-β3.

Fig. 1

Summary of stimulatory and inhibitory factors for mammotroph proliferation in rat and mouse pituitaries. Cell types of pituitary cells expressing each factor are shown in parentheses. GH, somatotroph; PRL, mammotroph, FS, folliculostellate cell; GTH, gonadotroph. VIP stimulates prolactin release, but its stimulatory role for mammotroph proliferation has not been clarified. References are cited and discussed in the text.

i0289-0003-21-6-601-f01.gif

The growth factors produced in pituitary glands act on pituitary cells as local mediators of estrogenic actions, and are involved in the regulation of pituitary cell turnover. It is not clear which is the primary factor involved in the regulation of mammotroph proliferation, however, these findings suggest that intrapituitary cell-to-cell interactions as well as hypothalamic and peripheral target tissue inputs play an important role in the control of pituitary secretory cells (Fig. 2).

Fig. 2

Regulatory system of proliferation and function of anterior pituitary cells. Anterior pituitary cells are controlled by hypothalamic hormones and peripheral hormones secreted from peripheral target glands. Circles in Brain indicate neurons, and those in Pituitary and Target gland indicate endocrine cells. Arrows indicate flows of signaling molecules (neurotransmitters, hormones and growth factors etc.). The anterior pituitary cells are also controlled by growth factors secreted from neighboring pituitary cells in a paracrine manner (intrapituitary cell-to-cell interaction). Mammotroph proliferation is regulated by various growth factors synthesized in pituitary glands (Fig. 1) as well as hypothalamic dopamine and ovarian estrogen.

i0289-0003-21-6-601-f02.gif

REFERENCES

1.

M. Aanestad, J. S. Røtnes, P. A. Torjesen, E. Haug, O. Sand, and T. Bjøro . 1993. Epidermal growth factor stimulates the prolactin synthesis and secretion in rat pituitary cells in culture (GH4C1 cells) by increasing the intracellular concentration of free calcium. Acta Endocrinol 128:361–366. Google Scholar

2.

H. Abe, M. E. Molitch, J. Van Wyk, and L. E. Underwood . 1983. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology 113:1319–1324. Google Scholar

3.

E. J. Abraham, W. J. Faught, and L. S. Frawley . 1998. Transforming growth factor β1 is a paracrine inhibitor of prolactin gene expression. Endocrinology 139:5174–5181. Google Scholar

4.

D. L. Allen, M. J. Low, R. G. Allen, and N. Ben-Jonathan . 1995. Identification of two classes of prolactin-releasing factors in intermediate lobe tumors from transgenic mice. Endocrinology 136:3093–3099. Google Scholar

5.

O. Amano, Y. Yoshitake, K. Nishikawa, and S. Iseki . 1993. Immunocytochemical localization of basic fibroblast growth factor in the rat pituitary gland. Arch Histol Cytol 56:269–276. Google Scholar

6.

J. Armstrong and G. V. Childs . 1997a. Changes in expression of epidermal growth factor receptors by anterior pituitary cells during the estrous cycle: cyclic expression by gonadotropes. Endocrinology 138:1903–1908. Google Scholar

7.

J. L. Armstrong and G. V. Childs . 1997b. Regulation of expression of epidermal growth factor receptors in gonadotropes by epidermal growth factor and estradiol: studies in cycling female rats. Endocrinology 138:5434–5441. Google Scholar

8.

M. Arras, A. Hoche, R. Bohle, P. Eckert, W. Riedel, and J. Schaper . 1996. Tumor necrosis factor-α in macrophages of heart, liver, kidney, and in the pituitary gland. Cell Tissue Res 285:39–49. Google Scholar

9.

M. A. Bach and C. A. Bondy . 1992. Anatomy of the pituitary insulin-like growth factor system. Endocrinology 131:2588–2594. Google Scholar

10.

R. R. Behringer, L. S. Mathews, R. D. Palmiter, and R. L. Brinster . 1988. Dwarf mice produced by genetic ablation of growth hormone-expressing cells. Genes Dev 2:453–461. Google Scholar

11.

C. Bert, V. Vande Vijver, M. Andries, P. Verhaert, P. Proost, B. De Vreese, J. Van Beeumen, H. Vankelecom, and C. Denef . 1999. Production of recombinant rat proopiomelanocortin 1–74 and characterization of its mitogenic action on pituitary lactotrophs. Mol Cell Endocrinol 154:111–122. Google Scholar

12.

F. R. Boockfor, J. P. Hoeffler, and L. S. Frawley . 1986. Estradiol induces a shift in cultured cells that release prolactin or growth hormone. Am J Physiol 250:E103–E105. Google Scholar

13.

B. Borgundvaag, J. E. Kudlow, S. G. Mueller, and S. R. George . 1992. Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor-α gene expression and growth in anterior pituitary, but not in uterus. Endocrinology 130:3453–3458. Google Scholar

14.

E. Borrelli, R. A. Heyman, C. Arias, P. E. Sawchenko, and R. M. Evans . 1989. Transgenic mice with inducible dwarfism. Nature 339:538–541. Google Scholar

15.

G. Burns and D. K. Sarkar . 1993. Transforming growth factor β1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen. Endocrinology 133:1444–1449. Google Scholar

16.

A. Cai, R. C. Bowers, J. P. J. Moore, and J. F. Hyde . 1998. Function of galanin in the anterior pituitary of estrogen-treated Fischer 344 rats: autocrine and paracrine regulation of prolactin secretion. Endocrinology 139:2452–2458. Google Scholar

17.

M. Candolfi, V. Zaldivar, A. De Laurentiis, G. Jaita, D. Pisera, and A. Seilicovich . 2002. TNF-α induces apoptosis of lactotropes from female rats. Endocrinology 143:3611–3617. Google Scholar

18.

A. J. Carrillo and C. J. Phelps . 1992. Quantification of vasoactive intestinal peptide immunoreactivity in the anterior pituitary glands of intact male and female, ovariectomized, and estradiol benzoate-treated rats. Endocrinology 131:964–969. Google Scholar

19.

L. J. Chew, V. Seah, D. Murphy, and D. Carter . 1996. Anterior pituitary vasoactive intestinal peptide mRNA is colocalised with prolactin mRNA in hyperoestrogenised rats. J Mol Endocrinol 16:211–220. Google Scholar

20.

J. S. Dasen, S. M. O'Connell, S. E. Flynn, M. Treier, A. S. Gleiberman, D. P. Szeto, F. Hooshmand, A. K. Aggarwal, and M. G. Rosenfeld . 1999. Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. Cell 97:587–598. Google Scholar

21.

A. De, T. E. Morgan, R. C. Speth, N. Boyadjieva, and D. K. Sarkar . 1996. Pituitary lactotrope expresses transforming growth factor β (TGF β) type II receptor mRNA and protein and contains 125I-TGF β 1 binding sites. J Endocrinol 149:19–27. Google Scholar

22.

C. Denef 1994. Paracrine mechanisms in the pituitary. In “The Pituitary Gland”. Ed by H. Imura Raven Press, Ltd. New York. pp. 351–378. Google Scholar

23.

C. Denef, J. Lu, and E. Swinnen . 2003. γ-MSH peptides in the pituitary: effects, target cells, and receptors. Ann NY Acad Sci 994:123–132. Google Scholar

24.

E. Ellerkmann, G. M. Nagy, and L. S. Frawley . 1991. Rapid augmentation of prolactin cell number and secretory capacity by an estrogen-induced factor released from the neurointermediate lobe. Endocrinology 129:838–842. Google Scholar

25.

E. Ellerkmann, G. M. Nagy, and L. S. Frawley . 1992a. α-melanocyte-stimulating hormone is a mammotrophic factor released by neurointermediate lobe cells after estrogen treatment. Endocrinology 130:133–138. Google Scholar

26.

E. Ellerkmann, T. E. Porter, G. M. Nagy, and L. S. Frawley . 1992b. N-acetylation is required for the lactotrope recruitment activity of α-melanocyte-stimulating hormone and β-endorphin. Endocrinology 131:566–570. Google Scholar

27.

J. Escalada, L. Cacicedo, J. Ortego, E. Melian, and F. Sanchez-Franco . 1996. Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide. Endocrinology 137:631–637. Google Scholar

28.

J. A. Fagin, A. Brown, and S. Melmed . 1988. Regulation of pituitary insulin-like growth factor-I messenger ribonucleic acid levels in rats harboring somatomammotropic tumors: implications for growth hormone autoregulation. Endocrinology 122:2204–2210. Google Scholar

29.

J. A. Fagin, C. Fernandez-Mejia, and S. Melmed . 1989. Pituitary insulin-like growth factor-I gene expression: regulation by triiodothyronine and growth hormone. Endocrinology 125:2385–2391. Google Scholar

30.

X. Fan and G. V. Childs . 1995. Epidermal growth factor and transforming growth factor-α messenger ribonucleic acids and their receptors in the rat anterior pituitary: localization and regulation. Endocrinology 136:2284–2293. Google Scholar

31.

R. Felix, U. Meza, and G. Cota . 1995. Induction of classical lactotropes by epidermal growth factor in rat pituitary cell cultures. Endocrinology 136:939–946. Google Scholar

32.

N. Ferrara, L. Schweigerer, G. Neufeld, R. Mitchell, and D. Gospodarowicz . 1987. Pituitary follicular cells produce basic fibroblast growth factor. Proc Natl Acad Sci USA 84:5773–5777. Google Scholar

33.

E. L. Finley, J. S. King, and J. S. Ramsdell . 1994. Human pituitary somatotropes express transforming growth factor-α and its receptor. J Endocrinol 141:547–554. Google Scholar

34.

J. S. Foster, D. C. Henley, S. Ahamed, and J. Wimalasena . 2001. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 12:320–327. Google Scholar

35.

L. S. Frawley and F. R. Boockfor . 1991. Mammosomatotropes: presence and functions in normal and neoplastic pituitary tissue. Endocr Rev 12:337–355. Google Scholar

36.

S. J. Frost, D. J. Simpson, and W. E. Farrell . 2001. Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-β1-induced expression of p15/INK4B. Mol Cell Endocrinol 176:29–37. Google Scholar

37.

P. J. Gage, M. L. Brinkmeier, L. M. Scarlett, L. T. Knapp, S. A. Camper, and K. A. Mahon . 1996. The Ames dwarf gene, df, is required early in pituitary ontogeny for the extinction of Rpx transcription and initiation of lineage-specific cell proliferation. Mol Endocrinol 10:1570–1581. Google Scholar

38.

H. Goda, T. Sakai, M. Kurosumi, and K. Inoue . 1998. Prolactin-producing cells differentiate from G0/G1-arrested somatotrophs in vitro: an analysis of cell cycle phases and mammotroph differentiation. Endocr J 45:725–735. Google Scholar

39.

O. Gomez and J. A. Balsa . 2003. Autocrine/paracrine action of pituitary vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen. Endocrinology 144:4403–4409. Google Scholar

40.

S. Gonzalez-Parra, J. Argente, J. A. Chowen, M. van Kleffens, J. W. van Neck, D. J. Lindenbeigh-Kortleve, and S. L. Drop . 2001. Gene expression of the insulin-like growth factor system during post-natal development of the rat pituitary gland. J Neuroendocrinol 13:86–93. Google Scholar

41.

C. G. Goodyer, L. De Stephano, H. J. Guyda, and B. I. Posner . 1984. Effects of insulin-like growth factors on adult male rat pituitary function in tissue culture. Endocrinology 115:1568–1576. Google Scholar

42.

D. Gospodarowicz and N. Ferrara . 1989. Fibroblast growth factor and the control of pituitary and gonad development and function. J Steroid Biochem 32:183–191. Google Scholar

43.

T. C. Hagen, M. A. Arnaout, W. J. Scherzer, D. R. Martinson, and T. L. Garthwaite . 1986. Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells. Neuroendocrinology 43:641–645. Google Scholar

44.

E. S. Haggi, A. I. Torres, C. A. Maldonado, and A. Aoki . 1986. Regression of redundant lactotrophs in rat pituitary gland after cessation of lactation. J Endocrinol 111:367–373. Google Scholar

45.

G. K. Haselbacher, M. E. Schwab, A. Pasi, and R. E. Humbel . 1985. Insulin-like growth factor II (IGF II) in human brain: regional distribution of IGF II and of higher molecular mass forms. Proc Natl Acad Sci USA 82:2153–2157. Google Scholar

46.

S. Hentges, N. Boyadjieva, and D. K. Sarkar . 2000. Transforming growth factor-β3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells. Endocrinology 141:859–867. Google Scholar

47.

S. Hentges, M. Pastorcic, A. De, N. Boyadjieva, and D. K. Sarkar . 2000. Opposing actions of two transforming growth factor-β isoforms on anterior lactotropic cell proliferation. Endocrinology 141:1528–1535. Google Scholar

48.

J. B. Hill, G. M. Nagy, and L. S. Frawley . 1991. Suckling unmasks the stimula-tory effect of dopamine on prolactin release: possible role for α-melanocyte-stimulating hormone as a mammotrope responsiveness factor. Endocrinology 129:843–847. Google Scholar

49.

J. Honda, Y. Manabe, R. Matsumura, S. Takeuchi, and S. Takahashi . 2003. IGF-I regulates pro-opiomelanocortin and GH gene expression in the mouse pituitary gland. J Endocrinol 178:71–82. Google Scholar

50.

J. Honda, S. Oomizu, Y. Kiuchi, N. Komatsu, S. Takeuchi, and S. Takahashi . 2000. Identification of epidermal growth factor mRNA-expressing cells in the mouse anterior pituitary. Neuroendocrinology 71:155–162. Google Scholar

51.

J. Honda, S. Takeuchi, H. Fukamachi, and S. Takahashi . 1998. Insulin-like growth factor-I and its receptor in mouse pituitary glands. Zool Sci 15:573–579. Google Scholar

52.

J. F. Hyde, M. G. Engle, and B. E. Maley . 1991. Colocalization of galanin and prolactin within secretory granules of anterior pituitary cells in estrogen-treated Fischer 344 rats. Endocrinology 129:270–276. Google Scholar

53.

K. Inoue and T. Sakai . 1991. Conversion of growth hormone-secreting cells into prolactin-secreting cells and its promotion by insulin and insulin-like growth factor-1 in vitro. Exp Cell Res 195:53–58. Google Scholar

54.

T. Kakeya, S. Takeuchi, and S. Takahashi . 2000. Epidermal growth factor, insulin, and estrogen stimulate development of prolactin-secreting cells in cultures of GH3 cells. Cell Tissue Res 299:237–243. Google Scholar

55.

T. Kakeya, S. Takeuchi, and S. Takahashi . 2002. Induction of mammotroph development by a combination of epidermal growth factor, insulin, and estradiol-17β in rat pituitary tumor GH3 cells. Zool Sci 19:789–795. Google Scholar

56.

L. M. Kaplan, S. M. Gabriel, J. I. Koenig, M. E. Sunday, E. R. Spindel, J. B. Martin, and W. W. Chin . 1988. Galanin is an estrogen-inducible, secre-tory product of the rat anterior pituitary. Proc Natl Acad Sci USA 85:7408–7412. Google Scholar

57.

R. D. Kineman, W. J. Faught, and L. S. Frawley . 1992. Steroids can modulate transdifferentiation of prolactin and growth hormone cells in bovine pituitary cultures. Endocrinology 130:3289–3294. Google Scholar

58.

H. Kobayashi, J. Fukata, N. Murakami, T. Usui, O. Ebisui, S. Muro, I. Hanaoka, K. Inoue, H. Imura, and K. Nakao . 1997. Tumor necrosis factor receptors in the pituitary cells. Brain Res 758:45–50. Google Scholar

59.

M. S. Kobrin, S. L. Asa, J. Samsoondar, and J. E. Kudlow . 1987. α-transforming growth factor in the bovine anterior pituitary gland: secretion by dispersed cells and immunohistochemical localization. Endocrinology 121:1412–1416. Google Scholar

60.

K. Koves, P. E. Gottschall, T. Gorcs, J. G. Scammell, and A. Arimura . 1990. Presence of immunoreactive vasoactive intestinal polypeptide in anterior pituitary of normal male and long term estrogen-treated female rats: a light microscopic immunohistochemical study. Endocrinology 126:1756–1763. Google Scholar

61.

J. E. Kudlow and M. S. Kobrin . 1984. Secretion of epidermal growth factor-like mitogens by cultured cells from bovine anterior pituitary glands. Endocrinology 115:911–917. Google Scholar

62.

E. Kulig, L. Jin, X. Qian, E. Horvath, K. Kovacs, L. Stefaneanu, B. W. Scheithauer, and R. V. Lloyd . 1999. Apoptosis in nontumorous and neo-plastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol 154:767–774. Google Scholar

63.

K. S. Lam, R. M. Lechan, N. Minamitani, T. P. Segerson, and S. Reichlin . 1989. Vasoactive intestinal peptide in the anterior pituitary is increased in hypothyroidism. Endocrinology 124:1077–1084. Google Scholar

64.

L. Langouche, K. Pals, and C. Denef . 2002. Structure-activity relationship and signal transduction of γ-MSH peptides in GH3 cells: further evidence for a new melanocortin receptor. Peptides 23:1077–1086. Google Scholar

65.

J. I. Lara, M. J. Lorenzo, L. Cacicedo, R. M. Tolón, J. A. Balsa, J. López-Fernández, and F. Sánchez-Franco . 1994. Induction of vasoactive intestinal peptide gene expression and prolactin secretion by insulin-like growth factor I in rat pituitary cells: evidence for an autoparacrine regulatory system. Endocrinology 135:2526–2532. Google Scholar

66.

G. H. Larson, R. D. Koos, M. A. Sortino, and P. M. Wise . 1990. Acute effect of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay. Endocrinology 126:927–932. Google Scholar

67.

M. Laudon, D. A. Grossman, and N. Ben-Jonathan . 1990. Prolactin-releasing factor: cellular origin in the intermediate lobe of the pituitary. Endocrinology 126:3185–3192. Google Scholar

68.

L. M. Lazar and M. Blum . 1992. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-α mRNA in mouse brain by a quantitative nuclease protection assay. J Neurosci 12:1688–1697. Google Scholar

69.

S. Li, E. B. Crenshaw 3rd, E. J. Rawson, D. M. Simmons, L. W. Swanson, and M. G. Rosenfeld . 1990. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 347:528–533. Google Scholar

70.

H. M. Lloyd, J. D. Meares, and J. Jacobi . 1975. Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells. Nature 225:497–498. Google Scholar

71.

F. Mallo, E. Wilson, C. B. Whorwood, S. Singh, and M. C. Sheppard . 1995. Basic and acidic fibroblast growth factor increase prolactin mRNA in a dose-dependent and specific manner in GH3 cells. Mol Cell Endocrinol 114:117–125. Google Scholar

72.

M. Marcinkiewicz, R. Day, N. G. Seidah, and M. Chretien . 1993. Ontogeny of the prohormone convertases PC1 and PC2 in the mouse hypophysis and their colocalization with corticotropin and α-melanotropin. Proc Natl Acad Sci USA 90:4922–4926. Google Scholar

73.

F. Marin and J. Boya . 1995. Immunocytochemical localization of basic fibroblast growth factor in the human pituitary gland. Neuroendocrinology 62:523–529. Google Scholar

74.

J. Massague 1990. Transforming growth factor-α: A model for membrane-anchored growth factors. J Biol Chem 265:21393–21396. Google Scholar

75.

R. Matsumura, C. Takagi, T. Kakeya, K. Okuda, S. Takeuchi, and S. Takahashi . 2003. α-Melanocyte-stimulating hormone stimulates prolactin secretion through melanocortin-3 receptors expressed in mammotropes in the mouse pituitary. Neuroendocrinology 78:96–104. Google Scholar

76.

J. McAndrew, A. J. Paterson, S. L. Asa, K. J. McCarthy, and J. E. Kudlow . 1995. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 136:4479–4488. Google Scholar

77.

K. M. Michels, W-H. Lee, A. Seltzer, J. M. Saavedra, and C. A. Bondy . 1993. Up-regulation of pituitary [125I]insulin-like growth factor-I (IGF-I) binding and IGF binding protein-2 and IGF-I gene expression by estrogen. Endocrinology 132:23–29. Google Scholar

78.

C. Missale, F. Boroni, M. Frassine, A. Caruso, and P. Spano . 1995. Nerve growth factor promotes the differentiation of pituitary mammotroph cells in vitro. Endocrinology 136:1205–1213. Google Scholar

79.

C. Missale, F. Boroni, S. Sigala, A. Buriani, M. Fabris, A. Leon, R. Dal Toso, and P. Spano . 1996. Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci USA 93:4240–4245. Google Scholar

80.

C. Missale, F. Boroni, S. Sigala, A. Zanellato, R. D. Toso, A. Balsari, and P. Spano . 1994. Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology 135:290–298. Google Scholar

81.

G. Morel, J. Besson, G. Rosselin, and P. M. Dubois . 1982. Ultrastructural evidence for endogenous vasoactive intestinal peptide-like immunoreactivity in the pituitary gland. Neuroendocrinology 34:85–89. Google Scholar

82.

Y. Morooka, S. Oomizu, S. Takeuchi, and S. Takahashi . 1998. Augmentation of prolactin release by α-melanocyte stimulating hormone is possibly mediated by melanocortin 3-receptors in the mouse anterior pituitary cells. Zool Sci 15:567–572. Google Scholar

83.

A. Mouihate and J. Lestage . 1995. Estrogen increases the release of epidermal growth factor from individual pituitary cells in female rats. J Endocrinol 146:495–500. Google Scholar

84.

S. G. Mueller and J. E. Kudlow . 1991. Transforming growth factor-β (TGF β) inhibits TGF α expression in bovine anterior pituitary-derived cells. Mol Endocrinol 5:1439–1446. Google Scholar

85.

I. Murai and N. Ben-Jonathan . 1990. Acute stimulation of prolactin release by estradiol: mediation by the posterior pituitary. Endocrinology 126:3179–3184. Google Scholar

86.

T. Murakami, A. Ohtsuka, T. Taguchi, A. Kikuta, and O. Ohtani . 1985. Blood vascular bed of the rat pituitary intermediate lobe, with special reference to its development and portal drainage into the anterior lobe. A scanning electron microscope study of vascular casts. Arch Histol Jpn 48:69–87. Google Scholar

87.

G. Nagy, J. J. Mulchahey, and J. D. Neill . 1988. Autocrine control of prolactin secretion by vasoactive intestinal peptide. Endocrinology 122:364–366. Google Scholar

88.

I. Ocrant, K. L. Valentino, A. R. Hoffman, R. L. Hintz, D. M. Wilson, and R. G. Rosenfeld . 1989. Structural characterization and immunohistochemical localization of receptors for insulin-like growth factor II in the rat pituitary gland. Neuroendocrinology 49:248–254. Google Scholar

89.

Y. Oishi, M. Okuda, H. Takahashi, T. Fujii, and S. Morii . 1993. Cellular proliferation in the anterior pituitary gland of normal adult rats: influence of sex, estrous cycle, and circadian change. Anat Rec 235:111–120. Google Scholar

90.

H. Oka, L. Jin, E. Kulig, B. W. Scheithauer, and R. V. Lloyd . 1999. Pituitary adenylate cyclase-activating polypeptide inhibits transforming growth factor-β1-induced apoptosis in a human pituitary adenoma cell line. Am J Pathol 155:1893–1900. Google Scholar

91.

L. E. Olson, J. S. Dasen, B. G. Ju, J. Tollkuhn, and M. G. Rosenfeld . 2003. Paired-like repression/activation in pituitary development. Recent Prog Horm Res 58:249–261. Google Scholar

92.

S. Oomizu, K. Chaturvedi, and D. K. Sarkar . 2004. Folliculostellate cells determine the susceptibility of lactotropes to estradiol's mitogenic action. Endocrinology 145:1473–1480. Google Scholar

93.

S. Oomizu, J. Honda, S. Takeuchi, T. Kakeya, T. Masui, and S. Takahashi . 2000. Transforming growth factor-α stimulates proliferation of mammotrophs and corticotrophs in the mouse pituitary. J Endocrinol 165:493–501. Google Scholar

94.

S. Oomizu and S. Takahashi . 1996. Insulin stimulates the proliferation of mouse anterior pituitary cells in vitro. Biomed Res 17:365–371. Google Scholar

95.

S. Oomizu, S. Takeuchi, and S. Takahashi . 1998. Stimulatory effect of insulin-like growth factor I on proliferation of mouse pituitary cells in serum-free culture. J Endocrinol 157:53–62. Google Scholar

96.

J. C. Patterson and G. V. Childs . 1994a. Nerve growth factor and its receptor in the anterior pituitary. Endocrinology 135:1689–1696. Google Scholar

97.

J. C. Patterson and G. V. Childs . 1994b. Nerve growth factor in the anterior pituitary: regulation of secretion. Endocrinology 135:1697–1704. Google Scholar

98.

P. Perumal and M. E. Vrontakis . 2003. Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone. J Endocrinol 179:145–154. Google Scholar

99.

R. G. Pestell, C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold . 1999. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20:501–534. Google Scholar

100.

T. E. Porter and L. S. Frawley . 1992. Neurointermediate lobe peptides recruit prolactin-secreting cells exclusively within the central region of the adenohypophysis. Endocrinology 131:2649–2652. Google Scholar

101.

T. E. Porter, C. D. Wiles, and L. S. Frawley . 1993. Lactotrope differentiation in rats is modulated by a milk-borne signal transferred to the neonatal circulation. Endocrinology 133:1284–1291. Google Scholar

102.

T. E. Porter, C. D. Wiles, and L. S. Frawley . 1994. Stimulation of lactotrope differentiation in in vitro by fibroblast growth factor. Endocrinology 134:164–168. Google Scholar

103.

M. Proesmans, A. Van Bael, M. Andries, and C. Denef . 1997. Mitogenic effects of nerve growth factor on different cell types in reaggre-gate cell cultures of immature rat pituitary. Mol Cell Endocrinol 134:119–127. Google Scholar

104.

X. Qian, L. Jin, J. P. Grande, and R. V. Lloyd . 1996. Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 137:3051–3060. Google Scholar

105.

J. S. Ramsdell 1991. Transforming growth factor-α and -β are potent and effective inhibitors of GH4 pituitary tumor cell proliferation. Endocrinology 128:1981–1990. Google Scholar

106.

D. Ray and S. Melmed . 1997. Pituitary cytokine and growth factor expression and action. Endocr Rev 18:206–228. Google Scholar

107.

P. Ren, B. W. Schelthauer, and J. Halper . 1994. Immunohistological localization of TGFα, EGF, IGF-I, and TGFβ in the normal human pituitary gland. Endocr Pathol 5:40–48. Google Scholar

108.

Y. Ren, J. Chien, Y. P. Sun, and G. V. Shah . 2001. Calcitonin is expressed in gonadotropes of the anterior pituitary gland: its possible role in paracrine regulation of lactotrope function. J Endocrinol 171:217–228. Google Scholar

109.

U. Renner, U. Pagotto, E. Arzt, and G. K. Stalla . 1996. Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumors pituitary function and growth: a review. Eur J Endocrinol 135:515–532. Google Scholar

110.

M. Roh, A. J. Paterson, S. L. Asa, E. Chin, and J. E. Kudlow . 2001. Stage-sensitive blockade of pituitary somatomammotrope development by targeted expression of a dominant negative epidermal growth factor receptor in transgenic mice. Mol Endocrinol 15:600–613. Google Scholar

111.

M. Roudbaraki, A. Lorsignol, L. Langouche, G. Callewaert, H. Vankelecom, and C. Denef . 1999. Target cells of γ3-melanocyte-stimulating hormone detected through intracellular Ca2+ responses in immature rat pituitary constitute a fraction of all main pituitary cell types, but mostly express multiple hormone phenotypes at the messenger ribonucleic acid level. Refractoriness to melanocortin-3 receptor blockade in the lacto-somatotroph lineage. Endocrinology 140:4874–4885. Google Scholar

112.

D. K. Sarkar, K. H. Kim, and S. Minami . 1992. Transforming growth factor-β 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol 6:1825–1833. Google Scholar

113.

F. Sasaki and Y. Iwama . 1988. Sex difference in prolactin and growth hormone cells in mouse adenohypophysis: stereological, morphometric, and immunohistochemical studies by light and electron microscopy. Endocrinology 123:905–912. Google Scholar

114.

J. Schechter, C. Stauber, J. J. Windle, and P. Mellon . 1995. Basic fibroblast growth factor: the neurotrophic factor influencing the ingrowth of neural tissue into the anterior pituitary of α-T7 transgenic mice. Neuroendocrinology 61:622–627. Google Scholar

115.

J. Schechter and R. Weiner . 1991. Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitaries of Fischer 344 and Sprague-Dawley rats. Endocrinology 129:2400–2408. Google Scholar

116.

J. Schwartz 2000. Intercellular communication in the anterior pituitary. Endocr Rev 21:488–513. Google Scholar

117.

J. Schwartz and R. Cherny . 1992. Intercellular communication within the anterior pituitary influencing the secretion of hypophysial hormones. Endocr Rev 13:453–475. Google Scholar

118.

K. M. Scully and M. G. Rosenfeld . 2002. Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231–2235. Google Scholar

119.

G. V. Shah, J. Chien, Y. P. Sun, S. Puri, and R. Ravindra . 1999. Calcitonin inhibits anterior pituitary cell proliferation in the adult female rats. Endocrinology 140:4281–4291. Google Scholar

120.

G. V. Shah, R. M. Epand, and R. C. Orlowski . 1988. Calcitonin inhibition of prolactin secretion in isolated rat pituitary cells. J Endocrinol 116:279–286. Google Scholar

121.

G. V. Shah, V. Pedchenko, S. Stanley, Z. Li, and W. K. Samson . 1996. Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Endocrinology 137:1814–1822. Google Scholar

122.

S. Sharma, S. Oomizu, T. Kakeya, T. Masui, S. Takeuchi, and S. Takahashi . 2003. Gene expression and the physiological role of transforming growth factor-α in the mouse pituitary. Zool Sci 20:83–89. Google Scholar

123.

N. Shirasawa and F. Yoshimura . 1982. Immunohistochemical and electron microscopical studies of mitotic adenohypophysial cells in different ages of rats. Anat Embryol 165:51–61. Google Scholar

124.

D. A. Sirbasku 1978. Estrogen induction of growth factors specific for hormone-responsive mammary, pituitary, and kidney tumor cells. Proc Natl Acad Sci USA 75:3786–3790. Google Scholar

125.

M. W. Sornson, W. Wu, J. S. Dasen, S. E. Flynn, D. J. Norman, S. M. O'Connell, I. Gukovsky, C. Carriere, A. K. Ryan, A. P. Miller, L. Zuo, A. S. Gleiberman, B. Andersen, W. G. Beamer, and M. G. Rosenfeld . 1996. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 384:327–333. Google Scholar

126.

Y. P. Sun, T. J. Lee, and G. V. Shah . 2002. Calcitonin expression in rat anterior pituitary gland is regulated by ovarian steroid hormones. Endocrinology 143:4056–4064. Google Scholar

127.

R. L. Sutherland, C. K. W. Watts, and C. L. Clarke . 1988. Oestrogen actions. In “Hormones and Their actions, Part I”. Ed by B. A. Cooke, R. J. B. King, and H. J. van der Molen . Elsevier Science Publishers BV (Biomedical Division). Amsterdam. pp. 197–215. Google Scholar

128.

S. Takahashi 1992. Heterogeneity and development of somatotrophs and mammotrophs in the rat. Zool Sci 9:901–924. Google Scholar

129.

S. Takahashi 1995. Development and heterogeneity of prolactin cells. Int Rev Cytol 157:33–98. Google Scholar

130.

S. Takahashi and S. Kawashima . 1982. Age-related changes in prolactin cell percentage and serum prolactin levels in intact and neonatally gonadectomized male and female rats. Acta Anat 113:211–217. Google Scholar

131.

S. Takahashi and S. Kawashima . 1987. Proliferation of prolactin cells in the rat: effects of estrogen and bromocryptine. Zool Sci 4:855–860. Google Scholar

132.

S. Takahashi, K. Okazaki, and S. Kawashima . 1984. Mitotic activity of prolactin cells in the pituitary glands of male and female rats of different ages. Cell Tissue Res 235:497–502. Google Scholar

133.

S. Takahashi, S. Sharma, S. Oomizu, J. Honda, and S. Takeuchi . 2002. Intrapituitary regulatory system of mammotrophs in the mouse. Arch Physiol Biochem 110:34–41. Google Scholar

134.

S. Tanaka and K. Kurosumi . 1986. Differential subcellular localization of ACTH and α-MSH in corticotropes of the rat anterior pituitary. Cell Tissue Res 243:229–238. Google Scholar

135.

G. S. Tannenbaum, H. J. Guyda, and B. I. Posner . 1983. Insulin-like growth factors: a role in growth hormone negative feedback and body weight regulation via brain. Science 220:77–79. Google Scholar

136.

M. S. Theas, A. De Laurentis, M. Lasaga, D. Pisera, B. H. Duvilanski, and A. Seilcovich . 1998. Effect of lipopolysaccharide on tumor necrosis factor and prolactin release from rat anterior pituitary cells. Endocrine 8:241–245. Google Scholar

137.

S. Theas, D. Pisera, B. Duvilanski, A. De Laurentiis, M. Pampillo, M. Lasaga, and A. Seilicovich . 2000. Estrogens modulate the inhibitory effect of tumor necrosis factor-α on anterior pituitary cell proliferation and prolactin release. Endocrine 12:249–255. Google Scholar

138.

D. Tilemans, D. Ramaekers, M. Andries, and C. Denef . 1997. Effect of POMC1-76, its c-terminal fragment γ3-MSH and anti-POMC1-76 antibodies on DNA replication in lactotrophs in aggregate cell cultures of immature rat pituitary. J Neuroendocrinol 9:627–637. Google Scholar

139.

J. Unger and W. Lange . 1997. Insulin receptors in the pituitary gland: morphological evidence for influence on opioid peptide-synthesizing cells. Cell Tissue Res 288:471–483. Google Scholar

140.

Y. Q. Wang, R. Yuan, Y-P. Sun, T-J. Lee, and G. V. Shah . 2003. Antiproliferative action of calcitonin on lactotrophs of the rat anterior pituitary gland: evidence for the involvement of transforming growth factor β1 in calcitonin action. Endocrinology 144:2164–2171. Google Scholar

141.

I. E. Wanke and O. P. Rorstad . 1990. Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: localization of binding to lactotropes. Endocrinology 126:1981–1988. Google Scholar

142.

S. M. Waters and J. E. Krause . 2000. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neurosci 95:265–271. Google Scholar

143.

D. Wynick, C. J. Small, A. Bacon, F. E. Holmes, M. Norman, C. J. Ormandy, E. Kilic, N. C. Kerr, M. Ghatei, F. Talamantes, S. R. Bloom, and V. Pachnis . 1998. Galanin regulates prolactin release and lactotroph proliferation. Proc Natl Acad Sci USA 95:12671–12676. Google Scholar

144.

S. Yamashita and S. Melmed . 1986. Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118:176–182. Google Scholar

145.

S. Yokoyama, L. Stefaneanu, and K. Kovacs . 1997. Pituitary insulin-like growth factors. Endocr Pathol 8:167–179. Google Scholar

146.

T. Yoneda, R. M. Lyall, M. M. Alsina, P. E. Persons, A. P. Spada, A. Levitzki, A. Zilberstein, and G. R. Mundy . 1991. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 51:4430–4435. Google Scholar

147.

T. Zheng, C. Villalobos, K. D. Nusser, T. W. Gettys, W. J. Faught, J. P. Castaño, and L. S. Frawley . 1997. Phenotypic characterization and functional correlation of α-MSH binding to pituitary cells. Am J Physiol 272:E282–E287. Google Scholar
Sumio Takahashi "Intrapituitary Regulatory System of Proliferation of Mammotrophs in the Pituitary Gland," Zoological Science 21(6), 601-611, (1 June 2004). https://doi.org/10.2108/zsj.21.601
Received: 29 March 2004; Published: 1 June 2004
JOURNAL ARTICLE
11 PAGES


SHARE
ARTICLE IMPACT
Back to Top